A Study of Avutometinib and Defactinib in People With Thyroid Cancer

Part of paid clinical trials in Basking Ridge, New Jersey.

Sponsor
Memorial Sloan Kettering Cancer Center
Study ID
NCT06007924
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Thyroid Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Avutometinib — DRUG
    Avutometinib 3.2 mg twice weekly 3 weeks on/1 week off
  • Defactinib — DRUG
    Defactinib 200 mg twice daily 3 weeks on/1 week off

Study Details

The researchers are doing this study to find out if the combination of avutometinib and defactinib is an effective treatment for RAF dimer-driven radioiodine-refractory differentiated thyroid cancer or anaplastic thyroid cancer. The researchers will also test whether avutometinib and defactinib is a safe treatment that causes few or mild side effects.

Key Dates

Start date
Aug 16, 2023
Status verified
Mar 2026
Primary completion
Aug 16, 2027
Completion
Aug 16, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Radioiodine-refractory (RAIR), recurrent and/or metastatic differentiated thyroid cancer (DTC)
    Patients will be treated with avutometinib 3.2 mg twice weekly and defactinib 200 mg twice daily, both 3 weeks on/1 week off.
  • Experimental: Anaplastic thyroid cancer (ATC)
    Patients will be treated with avutometinib 3.2 mg twice weekly and defactinib 200 mg twice daily, both 3 weeks on/1 week off.

Primary Outcome Measure

overall response rate (ORR) cohort A [ Time Frame: up to 2 years ]

Central Contacts

Locations (7)

FacilityCityStateZIPSite coordinators
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)Basking RidgeNew Jersey07920
Alan Ho, MD. PhD
646-608-3774
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)MiddletownNew Jersey07748
Alan Ho, MD, PhD
646-608-3774
Memorial Sloan Kettering Bergen (Limited Protocol Activities)MontvaleNew Jersey07645
Alan Ho, MD, PhD
646-608-3774
Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities)CommackNew York11725
Alan Ho, MD, PhD
646-608-3774
Memorial Sloan Kettering Westchester (Limited Protocol Activities)HarrisonNew York10604
Alan Ho, MD, PhD
646-608-3774
Memorial Sloan Kettering Cancer Center (All Protocol Activities)New YorkNew York10065
Alan Ho, MD. PhD
646-608-3774
Alan Ho, MD, PhD (PRINCIPAL_INVESTIGATOR)
Memorial Sloan Kettering Nassau (Limited Protocol Activities)Rockville CentreNew York11553
Alan Ho, MD, PhD
646-608-3774

Find similar trials in Basking Ridge, NJ

By research site
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)· Basking Ridge, NJMemorial Sloan Kettering Monmouth (Limited Protocol Activities)· Middletown, NJMemorial Sloan Kettering Bergen (Limited Protocol Activities)· Montvale, NJMemorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities)· Commack, NYMemorial Sloan Kettering Westchester (Limited Protocol Activities)· Harrison, NYMemorial Sloan Kettering Cancer Center (All Protocol Activities)· New York, NY

Related Studies